drugset / Trial / NCT02832999

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

NCT02832999

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic. Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day changes in insulin secretion and insulin sensitivity.

Timeline

Start
2016-01
Primary completion
2016-09
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.2 mg Subcutaneous
Comparator Vildagliptin Other / unclassified 100 mg